Latest revenue
$125.4K
as of 2025-12-31
Latest net income
$-8.0M
as of 2025-12-31
Net margin
-6350.6%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ACXP is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.2M
- Enterprise value
- $-2.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.03×
- Dividend yield
- 0.0%
- 52-wk high
- $8.34
- 52-wk low
- $0.29
- Beta
- —
- Shares out
- 4.3M
5-year trend
What this company does
Acurx Pharmaceuticals is a clinical-stage biotech developing antibiotics that target hard-to-treat bacterial infections, led by ibezapolstat for C. difficile infection. The company generates no product revenue and funds operations by repeatedly issuing stock, raising roughly $7.8 million through registered direct offerings, warrant exercises, and an equity line of credit in the first nine months of 2025. With only $5.9 million in cash, a $73.7 million accumulated deficit, and heavy reliance on dilutive financings following a reverse stock split, Acurx faces acute funding pressure as it pushes ibezapolstat toward Phase 3.
Generated from ACXP's filing dated 2026-05-11
Key risks
- Cash runway short: $5.9M cash vs. $5.6M nine-month operating burn implies under one year of liquidity without further dilutive financing.
- Severe dilution: shares outstanding more than doubled from 851,534 to 1,800,299 YTD via multiple offerings, ELOC, and warrant exercises.
- Going-concern signals: accumulated deficit of $73.7M, no revenue, recent reverse stock split, and continued reliance on registered direct offerings and equity line.
Generated from ACXP's filing dated 2026-05-11
Profitability
Operating margin
-6450.6%
90.8%Net margin
-6350.6%
90.9%Return on equity
-151.2%
93.4%Return on assets
-103.6%
71.7%Leverage
Debt / equity
0.46×
91.3%Debt / assets
31.5%
62.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-1.7M | +21.8% | — |
Q4 2025 2025-12-31 | — | — | $-1.6M | +43.3% | — |
Q3 2025 2025-09-30 | — | — | $-2.0M | +29.4% | — |
Q2 2025 2025-06-30 | — | — | $-2.2M | +45.5% | — |
Q1 2025 2025-03-31 | — | — | $-2.1M | +50.9% | — |
Q4 2024 2024-12-31 | — | — | $-2.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-2.8M | +9.4% | — |
Q2 2024 2024-06-30 | — | — | $-4.1M | -19.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ACXP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACXP
Institutional value
$474.6K
Total shares held
148.0K
Distinct holders
14
-4 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 54.6K | $202.7K | +43.9K (+408.6%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 31.1K | $115.4K | — | New |
| 3 | VANGUARD FIDUCIARY TRUST CO | 16.2K | $60.1K | — | New |
| 4 | Prospect Financial Services LLC | 13.8K | $51.1K | -6.0K (-30.5%) | Trimmed |
| 5 | UBS Group AG | 6.3K | $23.4K | +6.1K (+3634.9%) | Added |
| 6 | WELLS FARGO & COMPANY/MN | 2.3K | $8.5K | +0 (+0.0%) | No change |
| 7 | Westside Investment Management, Inc. | 1.6K | $6.1K | — | New |
| 8 | NBC SECURITIES, INC. | 1.5K | $5.6K | +0 (+0.0%) | No change |
| 9 | GROUP ONE TRADING LLC | 245 | $909 | -38 (-13.4%) | Trimmed |
| 10 | Cornerstone Planning Group LLC | 167 | $334 | +0 (+0.0%) | No change |
| 11 | BlackRock, Inc. | 60 | $223 | +0 (+0.0%) | No change |
| 12 | Cambridge Investment Research Advisors, Inc. | 20.0K | $74 | — | New |
| 13 | SBI Securities Co., Ltd. | 6 | $22 | -7 (-53.8%) | Trimmed |
| 14 | CITIGROUP INC | 1 | $4 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With only $5.9M cash and $6.5M nine-month burn, why should investors believe you avoid another dilutive raise before mid-2026?
- 2
Share count more than doubled to 1.8M post-split in nine months—what's the ceiling on equity line issuance before another reverse split?
- 3
R&D fell 66% YoY to $430K this quarter—is ibezapolstat's Phase 3 program actually progressing or being quietly throttled?
Refreshed when ACXP files a new report · last from 2026-05-11
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.